Summary

State-owned pharmaceutical company PT Kimia Farma Tbk (KAEF) has lowered the price of polymerase chain reaction (PCR) tests in response to the Ministry of Health's decision to reduce the tariff. The company's CEO, Verdi Budidarmo, said that the move was in line with the Directorate General of Health Services' Circular No. HK.02.02/I/2824/2021 on the Maximum Tariff Limit for Reserve Transcription Polymerase Chain Reaction (RT-PCR) Examinations, which took effect on Tuesday, August 17, 2021. The company has also lowered the price of antigen rapid tests. Kimia Farma is committed to providing the best service to the Indonesian people, according to Budidarmo.
Agus Chandra, the acting CEO of PT Kimia Farma Diagnostika (KFD), said that the company would do its best to comply with the order to lower the price of PCR tests. The company has reduced the price of PCR tests to IDR 495,000 and the price of antigen rapid tests to IDR 85,000 for regular types and IDR 125,000 for the Abbot Panbio brand. Kimia Farma, as part of the State-owned Pharmaceutical Holding, is committed to providing the best Covid-19 testing service to all Indonesians, according to Chandra.
Kimia Farma is ready to assist the government in conducting Covid-19 testing, according to Chandra. The company's clinics that conduct PCR and antigen rapid tests will adhere to professional standards. The move is expected to make it easier for Indonesians to access Covid-19 testing, which will contribute to the overall improvement of Indonesia's health climate.